---
title: "Cytek reaffirms $205M-$212M 2026 revenue outlook as US growth rebounds"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285651605.md"
description: "Cytek Biosciences (CTKB) reported Q1 2026 revenue of $44.1 million, a 6% increase from $41.5 million in Q1 2025. CEO Wenbin Jiang noted this growth indicates a return to normal market conditions in the U.S. The company reaffirms its revenue outlook for 2026, projecting between $205 million and $212 million."
datetime: "2026-05-08T02:17:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285651605.md)
  - [en](https://longbridge.com/en/news/285651605.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285651605.md)
---

# Cytek reaffirms $205M-$212M 2026 revenue outlook as US growth rebounds

Earnings Call Insights: Cytek Biosciences (CTKB) Q1 2026 Management View "First quarter 2026 revenue was $44.1 million, representing 6% growth year-over-year compared to $41.5 million in Q1 2025," said President, CEO & Chairman of the Board Wenbin Jiang, adding that the quarter reflected "a return to normal market conditions in the U.S." and "conti...

### Related Stocks

- [CTKB.US](https://longbridge.com/en/quote/CTKB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Lifeward Delays Quarterly Report Amid Deal Accounting](https://longbridge.com/en/news/286586728.md)
- [SeaStar Medical Q1 revenue rises on QUELIMMUNE growth](https://longbridge.com/en/news/286310505.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Microbot Medical Launches Full Commercial LIBERTY System Rollout](https://longbridge.com/en/news/286423065.md)
- [Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/286822028.md)